Phocus
Are You Eligible?The purpose of this research study is to assess the safety and tolerability of inhaled mosliciguat by dry-powder inhaler for treatment of Interstitial Lung Disease.
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
Pulmovant, Inc. is conducting a study of an investigational drug, called mosliciguat, for the treatment of PH-ILD. The main goals of this study are to learn how well the study drug works and how safe the study drug is. Depending on the study phase, you may receive a placebo, which is a capsule that looks like mosliciguat but contains no medicine and is not expected to have any therapeutic effect. This is done to allow the Sponsor to see if mosliciguat works as well as or better than the placebo. The treatment given is a daily inhaler and you will have up to 55 visits, which will include 30 clinic visits in person and 25 virtual visits at home.
Eligibility
- Adults aged 18-80 years
- Patients with Group 3 Pulmonary Hypertension- Interstitial Lung Disease (PH-ILD)
Lead investigator
- Dr John Feenstra
Clinical trial coordinator
- Chris Henderson
Technical title
A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Register your interest
If you would like more information about this clinical trial, please complete the contact form below.